Literature DB >> 1425618

Local cerebral blood flow and CO2 reactivity during prostaglandin E1-induced hypotension in patients undergoing cerebral aneurysm surgery.

K Abe1, M Nishimura, I Yoshiya.   

Abstract

The effects of prostaglandin E1 (PGE1) on local cerebral blood flow and CO2 reactivity were studied in 30 patients undergoing cerebral aneurysm surgery in eight of whom the aneurysm had not ruptured and was an incidental finding. The aneurysms were clipped at various intervals depending upon clinical conditions. Blood flow on the open brain surface was measured with a thermal gradient blood flow-meter. Hypotension was initially induced with 0.1 microgram kg-1 min-1 of PGE1 and subsequently adjusted to maintain the mean arterial blood pressure at about 70 mmHg. Local cerebral blood flow and CO2 reactivity were studied during and after PGE1 administration. Both were preserved, but CO2 reactivity values were lower in patients in whom the aneurysm had ruptured than in those in whom it had not ruptured. PGE1 may be an appropriate drug with which to induce hypotension during cerebral aneurysm surgery because cerebral blood flow and CO2 reactivity is preserved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425618

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  2 in total

1.  Low-dose but not high-dose prostaglandin E(1) improves the histological outcome of severe forebrain ischemia in rats.

Authors:  Yoshihide Miura; Kaoru Kanazawa; Noriko Yokoo; Kazue Iizawa; Masayuki Okada; Shinya Oda; Masaki Nakane
Journal:  J Anesth       Date:  2010-02-18       Impact factor: 2.078

2.  Time Course of Cerebrovascular Reactivity in Patients Treated for Unruptured Intracranial Aneurysms: A One-Year Transcranial Doppler and Acetazolamide Follow-Up Study.

Authors:  Marianne Lundervik Bøthun; Øystein Ariansen Haaland; Nicola Logallo; Frode Svendsen; Lars Thomassen; Christian A Helland
Journal:  Biomed Res Int       Date:  2018-04-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.